HYTN Shareholders Approve Peptide Development Labs Spin-Out
PUBT · 1d ago
Share
Listen to the news
- HYTN Innovations shareholders voted 100% in favor of separating Peptide Development Labs at today's annual general and special meeting.
- Completion is expected on or about November 17, 2026, subject to final court approval, concurrent PDL financing and Canadian Securities Exchange approval.
- New HYTN common shares and PDL common shares are expected to begin trading on November 18, 2026.
- PDL has applied to list on the Canadian Securities Exchange under “PEPT,” subject to meeting listing requirements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HYTN Innovations Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121705PRIMZONEFULLFEED9876925) on November 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending